Inhaled anesthetics are a chemically diverse collection of hydrophobic molecules that robustly 12 activate TWIK related K+ channels (TREK-1) and reversibly induce loss of consciousness. For a 13 hundred years anesthetics were speculated to target cellular membranes, yet no plausible 14 mechanism emerged to explain a membrane effect on ion channels. Here we show that inhaled 15 anesthetics (chloroform and isoflurane) activate TREK-1 channels through disruption of ordered 16 lipid domains (rafts). Super resolution imaging shows anesthetic raft disruption expels the 17 enzyme phospholipase D2 (PLD2), activating TREK-1. Catalytically dead PLD2 robustly blocks 18 anesthetic specific TREK-1 currents in whole cell patch-clamp. Addition of a PLD2 binding-site 19 renders the anesthetic-insensitive TRAAK channel sensitive. General anesthetics chloroform, 20 isoflurane, diethyl ether, xenon, and propofol all activate PLD2 in cellular membranes. Our 21 results suggest a two-step model of anesthetic TREK-1 activation. First, inhaled anesthetics 22 disrupt lipid rafts. Second, translocation and PLD2-dependent production of anionic lipid 23 activates TREK-1.
1 For many anesthetics (but not all), lipophilicity is the single most significant indicator of potency; Fig. S2a, Fig. 1f ). Methyl-b-cyclodextrin (MbCD), a chemical that disrupts GM1 domains by 1 removing cholesterol 15 , reduced the total number of domains 55% to 285 ± 42 per cell (mean ± 2 SEM, n=10). Binning the domains into small (0-150 nm) and large (150-500nm) revealed a clear 3 shift from small to large domains in the presence of inhaled anesthetics and revealed the 4 opposite effect after MbCD treatment ( Supplementary Fig. S2b ).
6
Mechanism of anesthetic sensitivity in TREK-1 channels 7 To distinguish the contribution of a putative indirect anesthetic effect from a direct one, we first 8 tested the contribution of direct binding to TREK-1 anesthetic sensitivity in a flux assay and 9 found no evidence for direct binding ( Supplementary Fig. S3a ). The most definitive experiment 10 to show a channel is directly modulated by a ligand is to purify and functionally reconstitute the 11 channel into lipid vesicle of known composition. Ion channels are now routinely expressed and 12 purified and assayed in vesicles. Purified channels robustly recapitulate small molecules binding 13 to channels in a cell free system using a flux assay 24 and in detergent 25 . We functionally 14 reconstituted purified TREK-1 into 16:1 phosphatidylcholine (PC) with 18:1 phosphatidylglycerol 15 (PG) (85:15 mol% ratio) liposomes and we found that neither chloroform nor isoflurane (1 mM, a 16 clinically relevant concentration) had a direct effect on TREK-1 activity ( Supplementary Fig.   17 S3a-b). Changing the lipids and ratios to 18:1PC/18:1PG (90/10 mol%) 25 also had no effect 18 (data not shown).
20
To assure that the channel was properly reconstituted and in conditions capable of increased 21 potassium flux, we reconstituted a mutant TREK-1 with double cysteines that allosterically 22 induced TREK-1 activation 25, 26 . Compared to the open TREK-1 control, inhaled anesthetics 23 failed to activate TREK-1 ( Supplementary Fig. S3a-b ). This result is inconsistent with direct 24 5 binding of anesthetics as the primary mechanism and lead us to consider an indirect 1 mechanism of TREK-1 activation.
3
Activation of TREK-1 by inhaled anesthetics, was previously shown to require a disordered loop 4 in the channel's C-terminus 10 ( Supplementary Fig. S3e ). The enzyme phospholipase D2 (PLD2) 5 also binds to and activates through same C-terminal region in TREK-1 27 . We recently showed 6 disruption of rafts (GM1 domains) by mechanical force activates PLD2 by substrate 7 presentation-the enzyme translocated out of rafts to disordered lipids and substrate 15 . If 8 anesthetics disrupt GM1 domains then we expect PLD2 to translocate and activate TREK-1, 9 leading us to hypothesize that raft disruption may be responsible for the anesthetic sensitivity 10 observed in TREK-1 channels.
12
To test the contribution of raft disruption to TREK-1 anesthetic sensitivity, we applied chloroform 13 to HEK293 cells expressing TREK-1 and a catalytically dead K758R PLD2 mutant (xPLD2) that 14 blocks anionic lipid (e.g. PA and PG) production 28 . We found xPLD2 blocked all detectible 15 chloroform specific current (Fig 2a-c) . This result suggests a two-step mechanism for anesthetic 16 action on TREK-1 channels. First, anesthetics disrupt GM1 domains releasing PLD2 and 17 second, the enzyme binds to the C-terminus and activates the channel through increased local 18 concentration of anionic lipid (Fig 2d) . The lack of TREK-1 current in the presence of anesthetic 19 further confirms our flux assay, i.e. direct binding of anesthetic is insufficient to activate the 20 channel absent PLD2 activity.
22
TRAAK is an anesthetic insensitive homolog of TREK-1. Interestingly, native TRAAK is also 23 insensitive to PLD2 27 . However, concatenating PLD2 to the N-terminus maximally activates 24 TRAAK and introduction of the PLD2 binding domain from TREK-1 renders TRAAK PLD2 25 sensitive 27 . If PLD2 is responsible for anesthetic sensitivity in TREK-1, we reasoned we could 26 6 render TRAAK anesthetic sensitive by introducing the PLD2 binding site into the C-terminus of 1 TRAAK (Fig. 3a ).
3
We over expressed the previously characterized PLD2 sensitive TRAAK chimera 27 4 (TRAAK/ctTREK) in HEK cells. As expected, in the presence of 1mM chloroform, 5 TRAAK/ctTREK robustly responded to chloroform (Fig. 3b,d) . To confirm the response is due to 6 PLD2 localization and not a direct interaction of the anesthetic with a structural feature of the 7 TREK-1 C-terminus, we over expressed the chimera with xPLD2 and found chloroform had no 8 effect on the channel. This result suggests the disordered C-terminus exerts its anesthetic effect 9 through binding to PLD2 and not direct binding of anesthetic to the C-terminus ( Fig. 3e ).
11
Anesthetics displace PLD2 out of GM1 rafts.
12
To confirm our two-step mechanism, we directly imaged PLD2 translocation out of lipid rafts 13 using dSTORM. Palmitoylation localizes proteins to rafts 29 including many ion channels 30 . 
17
Treating the N2A cells with chloroform or isoflurane (1 mM), caused PLD2 to translocate out of 18 GM1 domains (Fig 4a) . We verified translocation by cross correlation analysis-PLD2 strongly 19 associated with GM1 domains prior to treatment ( 1 If raft disruption is a general mechanism for anesthetics then all known activators of TREK-1 2 should also activate PLD2. We tested enzymatic activation of PLD2 by treating live cells with a 3 spectrum of chemically diverse inhaled anesthetics and monitoring activity using an assay that 4 couples choline release to a fluorescent signal 15 ( Fig. 5a-d ). Diethyl ether, chloroform, 5 isoflurane, and xenon all significantly activated PLD2 ( Fig. 5g ). Isoflurane had the greatest effect 6 ( Fig. 5g ) in N2A cells and chloroform had the greatest effect among inhaled anesthetics in 7 C2C12 myoblast cells ( Supplementary Fig. S5b ,f). This activation suggests anesthetic 8 disruption of GM1 domains allows PLD to access substrate and catalyze the production of 9 anionic signaling lipids (e.g. PA and PG) -a result similar to PLD2's activation by mechanical 10 disruption of GM1 domains 15 . Ketamine, an injectable NMDA receptor specific anesthetic 31 had 11 no effect on PLD activity, as expected for a direct ligand-protein interaction ( Fig. 5f,g) .
13
We also tested the injectable general anesthetics propofol 4 . Surprisingly, propofol robustly 14 activated PLD2 in N2A cells ( Fig. 5d ,g). If our mechanism is correct, then propofol should lead 15 to TREK-1 activation. As predicted, propofol (50 µM), robustly increased TREK-1 currents ( propofol works through the same pathway as inhaled anesthetics to activate TREK-1. In C2C12 20 cells, PLD2 activation required 400 µM concentrations of propofol suggesting cell specific 21 regulation of raft disruption or PLD2 translocation ( Supplementary Fig. S5d ,f).
23

DISCUSSION
24
We conclude inhaled anesthetics (at clinical concentrations) primarily disrupt GM1 domains to 25 elicit a response in TREK-1 channels. Anesthetics clearly disrupt the rafts, release PLD2, which 26 8 then binds to TREK-1 and increases the local concentration of anionic signaling lipid in the 1 membrane to activate TREK-1. Our proposed model is consistent with known properties of 2 inhaled anesthetics (summarized in Supplementary Fig. S5c-d ), specifically perturbation to 3 TREK-1 are through PLD2 and lipid binding sites 10, 11, 32 . The binding of PLD upon release from a 4 lipid nanodomain nicely explains how the C-terminus renders a channel anesthetic sensitive 5 when the domain is highly charged, devoid of structure, and has no obvious hydrophobicity 6 expected to bind an anesthetic ( Supplementary Fig. S5c-d ).
8
Anesthetic disruption of GM1 domains likely affects many proteins, including many ion 9 channels, as palmitoylation alone is sufficient to target proteins to GM1 domains 29 ; and many 10 ion channels are palmitoylated 30 . In theory, domain disruption could directly cause translocation 11 of a palmitoylated channel in a single step, exposing the channel to activating lipid as originally 12 proposed 13 . We chose a two-step system with PLD to avoid potential confounding effects on the 13 transmembrane domain of the channel, e.g., palmitoylation is unlikely to sense changes in 
19
At least three factors could influence the sensitivity/selectivity of TREK-1 to anesthetic 20 disruption; 1) the type of PLD2 lipidation, 2) regulation of the PLD2 affinity for the C-terminus, 
25
Alternatively, if the cell were to decrease desaturase activity or upregulate cholesterol and 26 9 saturated lipids, these changes would increase PLD2 localization to rafts and decrease the 1 sensitivity of TREK-1 to anesthetic. The anesthetic sensitivity of TASK channels, a homolog of 2 TREK-1, is likely governed by these principles since swapping the C-terminus of TASK for 3 TREK-1 also swaps the anesthetic sensitivity 10 .
5
Lastly, we considered the biophysical effect of anesthetics on the bulk membranes or 'non-raft' 6 membranes. We saw very little effect of clinical concentration of anesthetics on TREK-1 7 reconstituted into (DOPC) liposomes in our flux assay ( Supplementary Fig. 3a-b ), a mimic of 8 bulk lipids. This result agrees with previous studies that showed the effect of anesthetics on bulk 9 lipids is insufficient to activate a channel 34 at clinical concentrations despite the fact that 10 anesthetics fluidize and thin membranes 35 . TREK-1 is very sensitive to membrane thickness 11 (Nayebosadri unpublished data). It's possible we failed to test an optimal thickness that is 12 responsive in artificial systems, however, the fact that xPLD2 blocked all detectible anesthetic 13 currents in whole cells suggests, in a biological membrane, domain disruption and PLD2 14 translocation is the primary mechanism for anesthetic activation of TREK-1, not thinning of bulk 15 lipids. Our domain disruption mechanism does not preclude an anesthetic binding directly to 16 channels 2,4,36 . For example, local anesthetics inhibit TREK-1 through a distinct mechanism 17 (Pavel unpublished data).
19
Our data show anionic lipids are central mediators of anesthetic action on ion channels and 20 these results suggest lipid regulatory molecules and lipid binding sites in channels may be 21 effective targets for treating nervous system disorders and understanding the thresholds that 22 govern intrinsic nerve cell excitability. Thus the system we describe here obviously did not 
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